Making Moms a Priority

Center for Women's Emotional Wellness helps patients navigate the challenges of pregnancy, postpartum and beyond

Jul 29, 2024

6 min

Malina Spirito, M.Ed., MA

Veronica Chandler’s north Wilmington home is her sanctuary, and it shows. From the soft instrumental music to the scent of lavender to the comfy seats that invite visitors to put up their feet, the message is clear – rest, relax, recharge.


Original artwork by Veronica Chandler 


In this space, Chandler celebrates her rediscovered self, and it’s a journey she shares with all who visit. Part of the cozy feeling in her home comes from the artwork that lines the walls – mostly her own paintings and drawings created over the last six years as she navigates the challenges and triumphs of motherhood and discovers new ways to care for herself and those she loves.


After experiencing anxiety, panic attacks and profound depression following the birth of her daughter in 2018, Chandler sought help at the ChristianaCare Center for Women’s Emotional Wellness, where a combination of medication and therapy helped her feel healthier and reconnected. She also returned to a former passion – art.


“When I started painting, I found a way of silencing my brain, of calming it down. Being able to just focus on one thing on its own let my body regulate my nervous system,” she said. “I didn’t know what was happening to me. I just felt amazing.”


More than ‘baby blues’


Perinatal mood and anxiety disorders are among the most common complications that occur in pregnancy or in the first year after delivery, according to the American College of Obstetricians and Gynecologists.


Although many parents experience feelings of anxiety, fatigue and sadness in the first days with a new baby, postpartum depression can occur several months after childbirth. Symptoms are often more severe and can include extreme stress.


Despite increased awareness efforts in recent years, perinatal mood and anxiety disorders – including postpartum depression, which occurs in up to 20% of all births – remain underdiagnosed, untreated or undertreated, even though the health impact extends beyond the person giving birth, said Malina Spirito, Psy.D., MEd, director of the Center for Women’s Emotional Wellness.


The center opened in 2013 to help patients and their loved ones understand the challenges associated with perinatal mood and anxiety disorders. Since then, the program has tripled the number of clinicians and expanded services to include inpatient and outpatient consultations, ongoing psychotherapy and psychiatric medication management.



“Just because we know something is common does not mean we have to put up with it, especially because the effects will be lasting if we don’t address them,” Spirito said. “Perinatal mood disorders have an impact on the overall health of a family. When a mom feels better, the relationships they have with the people around them are better as well.”


Breaking the ‘super mom’ stereotype


Looking back, Chandler recognizes her struggles with sleeping and anxiety following the birth of her first child may have been signs of postpartum depression. The symptoms went away only to return after her daughter was born two years later.


Veronica Chandler sought help from the ChristianaCare Center for Women’s Emotional Wellness for postpartum depression. Caring for herself helped her rediscover her love of creating art.


Although overjoyed by her growing family, Chandler deeply missed her mother, who lived in her native Ecuador. Added to those challenges were longer stays in the hospital for Chandler, who had a Caesarean section birth, and for her daughter, who had some minor health issues.


In the weeks after giving birth, Chandler battled dizziness caused by anemia. Though exhausted by caring for a newborn, she couldn’t sleep. She constantly felt on edge, and her skin itched without relief.


Worried when her symptoms didn’t abate after three months, Chandler’s husband broached the idea of postpartum depression. For Chandler, it was a relief another person noticed something was wrong, but she was scared to think about what might be needed to get better.


“I think we’re programmed by our cultures and by our beliefs to think that we need to be ‘super moms’ and give everything we have,” said Chandler, who grew up in Ecuador and moved to the United States after marrying her husband.


“I was in such a fog that I didn’t know I could still shine and be happy and content. The default for so many moms is to pour until there’s nothing left.”


‘Rediscovering who I was’


Chandler sought help at the Center for Women’s Emotional Wellness and soon began taking an anti-depressant as part of her treatment. She also saw a therapist to talk about the feelings she was experiencing.


“Therapy was such a big part of this whole journey of rediscovering who I was. When you talk and someone listens, you figure things out,” Chandler said.


While on a trip to Arizona with a cousin, Chandler discovered kachina dolls, a Native American art form often used to provide guidance to young people and instill the connection between nature and the spirit. The intricately designed images further fueled Chandler’s reignited passion for art.


That passion helped Chandler manage the additional challenges brought on by the COVID-19 pandemic when her anxiety and depression resurfaced. Using painting, sculpture and other media, she has examined her own feelings relating to motherhood, family and society. Her work has been featured internationally in Vogue and closer to home in local art galleries.


“Some people like to cook, and some people like to write. Art is my creative outlet that allowed me to come back to who I am,” she said. “We all have to release that creativity in some way.”


Entering care sooner


While the Center for Women’s Emotional Wellness has always focused on pregnant and postpartum patients, it has grown to address mental health needs related to preconception health, including artificial reproductive technology such as in vitro fertilization, Spirito said. The center also sees patients grieving a pregnancy or neonatal loss.


More people are thinking about their mental health before they give birth, said Malina Spirito, Psy.D., MEd, director of the ChristianaCare Center for Women’s Emotional Wellness.


“One of the most notable observations I’ve seen over the years is that birthing people are entering care sooner. It isn’t uncommon for women to seek out consultation prior to getting pregnant about how to manage their mood disorder should they become pregnant,” said Megan O’Hara, LCSW, a behavioral health therapist with the Center for Women’s Emotional Wellness.


“Patients are educating themselves now and expecting their providers to consider their mental health as well as their physical health when getting care.”


Women’s mental health care also has become more accessible, said Cynthia Guy, LMSW, MSCC, a women’s health behavioral consultant with the Center for Women’s Emotional Wellness. Behavioral health services are available in every ChristianaCare women’s health practice, including virtual and in-person care.


“I can be the bridge connecting the patient with the resources they need to help them manage symptoms and what they are going through,” Guy said.


Filling the cup


As a result of her own experiences, Chandler teaches classes to help other mothers create their own art as a means of expression. It’s a small way of helping them to fill their own cup.


The woman who once hid in her own closet to hide her feelings speaks openly about mental health with the hope people will lose their preconceived ideas about depression and anxiety.


“I am so thankful for the journey and the many people I’ve met that have postpartum depression,” she said. “When we talk about what makes the best moms, I think the best mom is a healthy mom who is in balance and harmony.”

Connect with:
Malina Spirito, M.Ed., MA

Malina Spirito, M.Ed., MA

Psychologist

Malina Spirito, M.Ed., MA, is a psychologist with ChristianaCare.

Perinatal Mental HealthWomen's Mental Health
Powered by

You might also like...

Check out some other posts from ChristianaCare

3 min

New Study Finds Most Patients Can Safely Continue Weight Loss and Diabetes Drugs Before Gynecologic Surgery

Most patients taking popular weight loss and diabetes medications such as Ozempic and Wegovy can safely continue them before gynecologic surgery, according to a new journal article from ChristianaCare published in Obstetrics & Gynecology. The review found that serious anesthesia risks linked to these drugs are uncommon for most patients and can usually be managed through individualized planning rather than stopping the medication. The paper is the first to take a focused look at glucagon-like peptide-1 receptor agonists, commonly called GLP-1 drugs, in gynecologic surgery. These medications were first approved to treat diabetes and are now widely used to support weight loss and metabolic health, which refers to how the body processes sugar and energy. “Our study shows that the evidence does not support routinely stopping these medications before surgery and that the actual risk is low for most patients,” said Michelle Pacis, M.D., MPH, senior author of the study and a minimally invasive gynecologic surgeon at ChristianaCare. Why these medications raised concerns GLP-1 drugs work in part by slowing how quickly the stomach empties. This helps patients feel full longer, but it also raises concerns for surgery. Doctors worry that food remaining in the stomach could increase the risk of aspiration, when stomach contents enter the lungs during anesthesia. Because of this, early recommendations often advised stopping GLP-1 medications before surgery. The ChristianaCare review found that this approach was largely based on caution rather than strong evidence. The authors reviewed data from multiple studies, including large patient groups, that examined outcomes in people taking GLP-1 drugs during procedures. While some studies showed higher amounts of stomach contents, aspiration events were rare and occurred at rates similar to patients who were not taking the medications. New guidance reflects a change in thinking Recent national guidance from several medical societies now recommends a more tailored approach. Most patients can continue GLP-1 medications before surgery. For patients with higher risk factors, such as significant stomach symptoms or known delayed digestion, simple precautions can reduce risk. These precautions may include a clear liquid diet for 24 hours before surgery or closer monitoring during anesthesia. A clear liquid diet includes fluids like water, broth and clear juices. “This shift recognizes both the benefits of these medications and the importance of patient-specific decision making,” Pacis said. Why this matters for gynecologic surgery Many gynecologic surgeries require patients to be positioned in ways that can affect breathing and circulation. At the same time, many patients needing these procedures also have obesity or diabetes, which can increase surgical risk. GLP-1 medications can improve blood sugar control and support weight loss, helping patients enter surgery in better overall health and enhance recovery. Stopping these drugs without a clear reason may work against those benefits. Practical steps to support patient safety The study outlines several strategies care teams can use when patients remain on GLP-1 medications. These include thoughtful anesthesia planning, careful monitoring of heart and lung function, and, in select cases, the use of ultrasound to check stomach contents before surgery. “The goal is not to ignore risk, but to manage it wisely,” Pacis said. “For many patients, continuing these medications supports safer surgery and better recovery.” The authors note that more research is needed, particularly studies focused specifically on gynecologic surgery. Still, the findings offer clarity for patients and clinicians navigating a rapidly changing area of care. “This review helps bring evidence and balance to an issue that has caused a lot of confusion,” Pacis said. “It supports keeping patients on therapies that benefit their health whenever it is safe to do so.”

1 min

Two Research Scientists at the Cawley Center for Translational Cancer Research Earn Top Honors at UD Biology Research Day

Two rising cancer researchers from ChristianaCare’s Cawley Center for Translational Cancer Research were recognized for outstanding scientific contributions at the University of Delaware’s Annual Biology Research Day Conference on January 30, 2026. The awards highlight the strength and impact of colorectal cancer research underway at the Cawley Center. Anh Nguyen, a third year Ph.D. student, received the conference’s first place poster award for his project, “FGF19/FGFR4 Axis: A Key Driver in Tumor Growth and Treatment Resistance in Colorectal Cancer.” His research explores a signaling pathway that may lead to new strategies for targeting treatment resistant disease. Molly Lausten, a fifth year Ph.D. student, earned third place for her presentation, “Investigating the role of miR 27a 3p in the WNT signaling pathway and chemoresistance in colorectal cancer stem cells.” Her work examines a key microRNA that may influence resistance to therapy, a major challenge in treating aggressive tumors. “These awards reflect far more than individual excellence,” said Bruce M. Boman, M.D., Ph.D., MSPH, FACP, senior scientist and director of Cancer Genetics at the Cawley Center. “They show the power of rigorous, curiosity driven science to move the field forward. Molly and Anh are tackling some of the hardest questions in colorectal cancer, and their success speaks to the innovative environment we are building at ChristianaCare. I could not be more proud of their achievement and their commitment to improving outcomes for patients.”

3 min

Gene Editing Breakthrough Offers New Hope for Head and Neck Cancer Patients

Researchers at the ChristianaCare Gene Editing Institute have made an important advance in treating head and neck cancers. By using CRISPR gene editing, the team found a way to restore how well chemotherapy works in tumors that have stopped responding to treatment. Their results, now published in Molecular Therapy Oncology, could change how doctors treat these aggressive cancers and give new hope to many patients who face limited options. Head and neck cancer is the seventh most common cancer worldwide, and cases are expected to rise by 30 percent every year by 2030. Even with progress in surgery, chemotherapy and immunotherapy, many patients still reach a point where treatment no longer works. The ChristianaCare team aimed to solve this challenge at its source. Targeting the Heart of Drug Resistance The researchers focused on a gene called NRF2. This gene acts like a master switch that helps cancer cells survive stress and resist chemotherapy. Because NRF2 plays such a central role in tumor growth, the team chose to develop a genetic therapy that disables the gene itself rather than targeting a single protein, which is common in traditional drug development. Since NRF2 is a transcription factor, shutting it down in a lasting way is more likely to succeed through CRISPR gene editing. Their major advance was showing that CRISPR can successfully disrupt NRF2 in head and neck cancer cells and in esophageal cancer cells. This work builds on earlier studies in lung cancer, where blocking NRF2 made tumors more sensitive to chemotherapy and improved survival in animal models. “Our goal was to break through the wall of drug resistance that so many patients face,” said Natalia Rivera Torres, Ph.D., the study’s lead author. “By precisely editing the NRF2 gene, we can make cancer cells vulnerable again to standard treatments. This could improve outcomes and quality of life.” Precision Matters: The Power of Target Choice The study also showed that the location of the CRISPR cut within the NRF2 gene makes a big difference. The strongest results came from targeting exon 4, a part of the gene that controls a key section of the NRF2 protein. Editing this region reduced NRF2 levels by 90 percent and made cancer cells much more sensitive to chemotherapy. In comparison, editing exon 2 was less effective even though it still caused high levels of gene disruption. The team also found that a process called exon skipping, where sections of genetic code are rearranged, can affect the outcome of gene editing. This discovery highlights how important careful design and testing are when building gene editing therapies. A Platform for Broader Impact ChristianaCare researchers saw the same results in both head and neck cancer cells and esophageal cancer cells. This suggests the strategy could help treat many solid tumors that have high levels of NRF2 and are known for strong drug resistance. “This is more than just a single experiment,” said Eric Kmiec, Ph.D., director of the Gene Editing Institute and senior author of the study. “We are building a platform that can be adapted to different cancers. Our earlier work in lung cancer showed the promise of this approach, and now we see it working in other hard to treat tumors. It is an exciting step toward making gene editing a meaningful part of cancer treatment.” Looking Ahead: Toward Clinical Application With these strong results, the team is now focused on finding the safest and most effective way to deliver the gene editing tools directly to tumors. Their goal is to reduce how much standard treatment a patient needs in order to get the best result with fewer side effects. “Drug resistance is one of the biggest challenges in cancer care,” Rivera Torres said. “If we can overcome it with gene editing, we could give patients more time, better quality of life and a renewed sense of hope.” Kmiec added, “We are committed to moving this technology forward quickly while always keeping the patient in mind. The future of cancer treatment is personal, precise and, we believe, within reach.”

View all posts